JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: TBAJ-587, a diarylquinoline analog, is a novel and potent anti-tuberculosis agent which inhibits M.tb strain H37Rv growth with MIC90s of 0.006 and< 0.02 ug/mL in MABA and LORA assay, respectively. It demonstrated more potent in vitro and in vivo anti-tubercular activity, with greatly attenuated hERG blockade. It is as potent as bedaquiline against Mycobacterium tuberculosis, but with lower lipophilicity, higher clearance, and lower risk for QT prolongation. TBAJ-587 inhibits hERG channel minimally, attenuates inhibition of the cardiac potassium channel protein coded by the hERG, which is important for cardiac repolarization.
References: Bioorg Med Chem. 2019 Apr 1; 27(7):1292-1307.
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!